Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 11:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 85 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Primary Biliary Cirrhosis Clear all

Conditions: Primary Biliary Cirrhosis
Interventions: Obeticholic Acid (OCA), Placebo; Drug
Lead sponsor: Intercept Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 15
States / cities: Sacramento, California • San Diego, California • Aurora, Colorado + 11 more

Conditions: Liver Cirrhosis, Biliary
Interventions: Obeticholic Acid (OCA), Placebo; Drug
Lead sponsor: Intercept Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 11
States / cities: Rialto, California • Sacramento, California • Miami, Florida + 8 more

Conditions: Cholestasis
Interventions: Linerixibat; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 11
States / cities: Davis, California • West Hollywood, California • Miami, Florida + 8 more

Conditions: Primary Biliary Cholangitis
Interventions: K-808 (Dose A), K-808 (Dose B), Placebo; Drug
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 21
States / cities: Tucson, Arizona • Coronado, California • Los Angeles, California + 18 more

Conditions: Primary Biliary Cirrhosis
Interventions: Combination antiviral therapy, Placebo; Drug
Lead sponsor: University of Alberta; Other
Eligibility: 18 Years to 75 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 2
States / cities: Rochester, Minnesota • St Louis, Missouri

Conditions: Primary Sclerosing Cholangitis, Compensated Cirrhosis
Interventions: Cilofexor; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 16
States / cities: Chandler, Arizona • Pasadena, California • San Francisco, California + 11 more

Conditions: Primary Biliary Cholangitis
Interventions: Seladelpar 10 mg, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 43
States / cities: Chandler, Arizona • Pasadena, California • Sacramento, California + 32 more

Conditions: Liver Cirrhosis, Biliary
Interventions: tigecycline; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 2
States / cities: Saint Paul, Minnesota • Durham, North Carolina

Conditions: Primary Biliary Cirrhosis
Interventions: fenofibrate, placebo; Drug
Lead sponsor: University of Miami; Other
Eligibility: 21 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 2
States / cities: Miami, Florida • Rochester, Minnesota

Conditions: Primary Biliary Cholangitis (PBC)
Interventions: Elafibranor 80 mg, Elafibranor 120 mg, Placebo; Drug
Lead sponsor: Genfit; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 13
States / cities: Phoenix, Arizona • Miami, Florida • Weston, Florida + 9 more

Conditions: Primary Biliary Cirrhosis
Interventions: NGM282; Biological
Lead sponsor: NGM Biopharmaceuticals, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 6
States / cities: Phoenix, Arizona • Coronado, California • Detroit, Michigan + 3 more

Conditions: Pruritus
Interventions: EP547, Placebo; Drug
Lead sponsor: Escient Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 21
States / cities: Birmingham, Alabama • Phoenix, Arizona • Coronado, California + 17 more

Conditions: Primary Biliary Cholangitis
Interventions: APD334; Drug
Lead sponsor: Arena Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 4
States / cities: Sacramento, California • Houston, Texas • San Antonio, Texas + 1 more

Conditions: Liver Cirrhosis, Biliary
Interventions: INT-747, Ursodeoxycholic Acid (URSO), Placebo; Drug
Lead sponsor: Intercept Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 13
States / cities: Gainesville, Florida • Miami, Florida • Boston, Massachusetts + 9 more

Conditions: Biliary Cirrhosis, Primary
Interventions: Not listed
Lead sponsor: Target PharmaSolutions, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 711 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 39
States / cities: Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 31 more

Conditions: Primary Biliary Cirrhosis
Interventions: Genetic Analysis; Genetic
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 90 Years
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Primary Biliary Cirrhosis
Interventions: Moexipril; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: PBC, Primary Biliary Cirrhosis
Interventions: LUM001, Placebo, Ursodeoxycholic Acid; Drug
Lead sponsor: Mirum Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 17
States / cities: La Jolla, California • Sacramento, California • Miami, Florida + 14 more

Conditions: Pregnancy Related
Interventions: Elafibranor; Drug
Lead sponsor: Ipsen; Industry
Eligibility: Female only
Enrollment: 3 participants
Timeline: 2026 – 2039
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: Pruritus
Interventions: Linerixibat; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 2
States / cities: Orlando, Florida • San Antonio, Texas

Conditions: Primary Biliary Cholangitis
Interventions: Not listed
Lead sponsor: Intercept Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 4,577 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: San Diego, California

Conditions: Primary Biliary Cirrhosis
Interventions: NGM282, Placebo; Biological
Lead sponsor: NGM Biopharmaceuticals, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 7
States / cities: Phoenix, Arizona • Coronado, California • Detroit, Michigan + 4 more

Conditions: Primary Sclerosing Cholangitis
Interventions: Cilofexor, Placebo to match cilofexor; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 16
States / cities: Sacramento, California • San Francisco, California • Aurora, Colorado + 10 more

Conditions: Primary Biliary Cholangitis
Interventions: seladelpar 5-10 mg, seladelpar 10 mg, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 265 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 51
States / cities: Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 41 more

Search by objective public record fields.

Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis

Study of Obeticholic Acid (OCA) Evaluating Pharmacokinetics and Safety in Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment

Linerixibat Long-term Safety, and Tolerability Study

Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment.

Study of Combivir for Patients With Primary Biliary Cirrhosis

Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis

Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)

Pharmacokinetic Study Of Tigecycline In Adult Subjects With Primary Biliary Cirrhosis

Fenofibrate in Combination With Ursodeoxycholic Acid (UDCA) in Primary Biliary Cirrhosis

Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid

Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis

Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis

Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary Cholangitis

Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC)

A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis

Genetic Epidemiology of Primary Biliary Cirrhosis (PBC)

Moexipril for Primary Biliary Cirrhosis

Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis

Elafibranor Pregnancy Surveillance Program: A Study to Evaluate the Safety of Elafibranor During Pregnancy

Phase I Study of Linerixibat in Adults With Moderate Hepatic Impairment and Healthy Controls

Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients

Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis

Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis

ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)